Latest Content

Should EDs use AI to spot suicide risk? Explore evidence, bias concerns, false positives, and what accreditation mandates could mean for care.

Meta-analysis ranks add-on atypical antipsychotics for MDD, comparing symptom response and dropout risks to guide smarter next-step treatment.

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.

FDA grants Fast Track to Acadia’s remlifanserin for Alzheimer disease psychosis, targeting hallucinations and delusions as RADIANT trial advances toward 2026 data.

Why DSM reforms miss psychiatry’s key flaw: weak diagnostic validity—and how evidence-based validators could reshape diagnosis, research, and care.

Learn how clinicians manage bipolar disorder in women who may become pregnant—safer meds, contraception counseling, and relapse prevention.

Meta-analysis links traumatic brain injury to rising long-term psychosis risk; severity, age, and follow-up time guide smarter screening and care.

Learn how clinicians tackle mood and substance use disorders together, boost patient engagement, and expand evidence-based addiction medications for bipolar and alcohol use.

Oral THC/CBD combo rapidly eases severe dementia agitation in phase 2 trial, with sustained 12-week benefit and similar safety to placebo.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

How shifting cannabis laws shape potency, access, and risk—revealing why anxiety, paranoia, and psychosis can surge when users cross regulatory borders.

Learn how fast-acting oral zuranolone treats postpartum depression in days, with practical prescribing and breastfeeding guidance clinicians can use.

FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.